

# PRINCIPLES OF CLINICAL PHARMACOLOGY

Second Edition

**Arthur J. Atkinson Jr., M.D.**  
NIH Clinical Center  
Bethesda, MD 20892-1165

**Darrell R. Abernethy, M.D., Ph.D.**  
National Institute on Aging  
Geriatric Research Center  
Laboratory of Clinical Investigation  
Baltimore, MD 21224

**Charles E. Daniels, R.Ph., Ph.D., FASHP**  
Skaggs School of Pharmacy and  
Pharmaceutical Sciences  
University of California, San Diego  
San Diego, CA 92093-0657

**Robert L. Dedrick, Ph.D.**  
Office of Research Services, OD, NIH  
Division of Bioengineering and Physical Sciences  
Bethesda, MD 20892

**Sanford P. Markey, Ph.D.**  
National Institute of Mental Health, NIH  
Laboratory of Neurotoxicology  
Bethesda, MD 20892



ELSEVIER

Amsterdam • Boston • Heidelberg • London • New York  
Oxford • Paris • San Diego • San Francisco • Singapore  
Sydney • Tokyo



Academic Press is an imprint of Elsevier

Academic Press is an imprint of Elsevier  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
525 B Street, Suite 1900, San Diego, California 92101-4495, USA  
84 Theobald's Road, London WC1X 8RR, UK

This book is printed on acid-free paper. (∞)

Copyright © 2007, Elsevier Inc. All rights reserved.  
Except chapters 1, 2, 3, 4, 5, 11, 12, 14, 15, 16, 23, 24, 30, 31, 34, Appendix I and II  
which are in the public domain.

No part of this publication may be reproduced or transmitted in any form or by any  
means, electronic or mechanical, including photocopy, recording, or any information  
storage and retrieval system, without permission in writing from the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights  
Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333,  
E-mail: [permissions@elsevier.com](mailto:permissions@elsevier.com). You may also complete your request on-line  
via the Elsevier homepage (<http://elsevier.com>), by selecting "Support & Contact"  
then "Copyright and Permission" and then "Obtaining Permissions."

**Library of Congress Cataloging-in-Publication Data**  
Application Submitted

**British Library Cataloguing-in-Publication Data**  
A catalogue record for this book is available from the British Library.

ISBN 13: 978-0-12-369417-1  
ISBN 10: 0-12-369417-5

For information on all Academic Press publications  
visit our Web site at [www.books.elsevier.com](http://www.books.elsevier.com)

Printed in the United States of America  
06 07 08 09 10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

# Contents

---

Preface xv  
Contributors xvii

---

CHAPTER

**1**

**Introduction to Clinical Pharmacology**

ARTHUR J. ATKINSON, JR.

**Background 1**

Optimizing Use of Existing Medicines 1

Evaluation and Development of Medicines 2

**Pharmacokinetics 4**

Concept of Clearance 4

Clinical Assessment of Renal Function 5

Dose-Related Toxicity Often Occurs When Impaired

Renal Function is Unrecognized 5

---

PART

**I**

**PHARMACOKINETICS**

---

CHAPTER

**2**

**Clinical Pharmacokinetics**

ARTHUR J. ATKINSON, JR.

The Target Concentration Strategy 11

Monitoring Serum Concentrations of Digoxin as an  
Example 11

General Indications for Drug Concentration  
Monitoring 13

**Concepts Underlying Clinical Pharmacokinetics 13**

Initiation of Drug Therapy (Concept of Apparent  
Distribution Volume) 14

Continuation of Drug Therapy (Concepts of  
Elimination Half-Life and Clearance) 15

Drugs Not Eliminated by First-Order Kinetics 17

**Mathematical Basis of Clinical Pharmacokinetics 18**

First-Order Elimination Kinetics 18

Concept of Elimination Half-Life 19

Relationship of  $k$  to Elimination Clearance 19

Cumulation Factor 19

Plateau Principle 20

Application of Laplace Transforms to  
Pharmacokinetics 21

---

CHAPTER

**3**

**Compartmental Analysis of Drug  
Distribution**

ARTHUR J. ATKINSON, JR.

**Physiological Significance of Drug Distribution  
Volumes 25**

**Physiological Basis of Multicompartmental Models  
of Drug Distribution 27**

Basis of Multicompartmental Structure 27

Mechanisms of Transcapillary Exchange 28

**Clinical Consequences of Different Drug  
Distribution Patterns 30**

**Analysis of Experimental Data 31**

Derivation of Equations for a Two-Compartment  
Model 31

Calculation of Rate Constants and Compartment  
Volumes from Data 34

Different Estimates of Apparent Volume of Distribution 34

---

CHAPTER

**4**

**Drug Absorption and Bioavailability**

ARTHUR J. ATKINSON, JR.

Drug Absorption 37

Bioavailability 40

Absolute Bioavailability 41

Relative Bioavailability 42

*In Vitro* Prediction of Bioavailability 43

Kinetics of Drug Absorption after Oral

Administration 44

Time to Peak Level 46

Value of Peak Level 46

Use of Convolution/Deconvolution to Assess  
*in Vitro-in Vivo* Correlations 47

---

CHAPTER

**5**

**Effects of Renal Disease on  
Pharmacokinetics**

ARTHUR J. ATKINSON, JR. AND MARCUS M.  
REIDENBERG

Effects of Renal Disease on Drug Elimination 52

Mechanisms of Renal Handling of Drugs 53

Effects of Impaired Renal Function on Nonrenal  
Metabolism 54

Effects of Renal Disease on Drug Distribution 55

Plasma Protein Binding of Acidic Drugs 55

Plasma Protein Binding of Basic and Neutral  
Drugs 56

Tissue Binding of Drugs 56

Effects of Renal Disease on Drug Absorption 56

---

CHAPTER

**6**

**Pharmacokinetics in Patients Requiring  
Renal Replacement Therapy**

ARTHUR J. ATKINSON, JR. AND GREGORY M. SUSLA

Kinetics Of Intermittent Hemodialysis 59

Solute Transfer across Dialyzing Membranes 59

Calculation of Dialysis Clearance 61

Patient Factors Affecting Hemodialysis of  
Drugs 62

**Kinetics of Continuous Renal Replacement  
Therapy 65**

Clearance by Continuous Hemofiltration 65

Clearance by Continuous Hemodialysis 66

Extracorporeal Clearance during Continuous Renal  
Replacement Therapy 66

Clinical Considerations 67

Drug Dosing Guidelines for Patients Requiring  
Renal Replacement Therapy 67

Extracorporeal Therapy of Patients with Drug  
Toxicity 69

---

CHAPTER

**7**

**Effect of Liver Disease on  
Pharmacokinetics**

GREGORY M. SUSLA AND ARTHUR J. ATKINSON, JR.

Hepatic Elimination of Drugs 73

Restrictively Metabolized Drugs ( $ER < 0.3$ ) 74

Drugs with an Intermediate Extraction Ratio  
( $0.3 < ER < 0.7$ ) 75

Nonrestrictively Metabolized Drugs ( $ER > 0.70$ ) 75

Biliary Excretion of Drugs 75

Effects of Liver Disease on Pharmacokinetics 76

Acute Hepatitis 77

Chronic Liver Disease and Cirrhosis 78

Pharmacokinetic Consequences of Liver  
Cirrhosis 79

Use of Therapeutic Drugs in Patients with Liver  
Disease 80

Effects of Liver Disease on the Hepatic Elimination  
of Drugs 80

Effects of Liver Disease on the Renal Elimination of  
Drugs 82

Effects of Liver Disease on Patient Response 83

Modification of Drug Therapy in Patients with Liver  
Disease 84

---

CHAPTER

**8**

**Noncompartmental versus Compartmental  
Approaches to Pharmacokinetic Analysis**

DAVID M. FOSTER

Introduction 89

Kinetics, Pharmacokinetics, and Pharmacokinetic  
Parameters 90

Kinetics and the Link to Mathematics 90

Pharmacokinetic Parameters 91

- Noncompartmental Analysis** 92  
 Noncompartmental Model 92  
 Kinetic Parameters of the Noncompartmental Model 93  
 Estimating the Kinetic Parameters of the Noncompartmental Model 95  
**Compartmental Analysis** 97  
 Definitions and Assumptions 97  
 Linear, Constant-Coefficient Compartmental Models 99  
 Parameters Estimated from Compartmental Models 99  
**Noncompartmental versus Compartmental Models** 102  
 Models of Data vs Models of System 103  
 Equivalent Sink and Source Constraints 103  
 Recovering Pharmacokinetic Parameters from Compartmental Models 104  
**Conclusion** 105

## CHAPTER

**9****Distributed Models of Drug Kinetics**

PAUL F. MORRISON

- Introduction** 107  
**Central Issues** 107  
**Drug Modality I: Delivery across a Planar-Tissue Interface** 108  
 General Principles 108  
 Differences between the Delivery of Small Molecules and Macromolecules across a Planar Interface 114  
**Drug Modality II: Delivery from a Point Source — Direct Interstitial Infusion** 117  
 General Principles 117  
 Low-Flow Microinfusion Case 117  
 High-Flow Microinfusion Case 118  
**Summary** 126

## CHAPTER

**10****Population Pharmacokinetics**

RAYMOND MILLER

- Introduction** 129  
**Analysis of Pharmacokinetic Data** 129  
 Structure of Pharmacokinetic Models 129  
 Fitting Individual Data 130  
**Population Pharmacokinetics** 130  
 Population Analysis Methods 131  
**Model Applications** 134

- Mixture Models 134  
 Exposure-Response Models 136  
**Conclusions** 138

## PART

**II****DRUG METABOLISM AND TRANSPORT**

## CHAPTER

**11****Pathways of Drug Metabolism**

SANFORD P. MARKEY

- Introduction** 143  
**Phase I Biotransformations** 146  
 Liver Microsomal Cytochrome P450 Monooxygenases 146  
 CYP-Mediated Chemical Transformations 149  
 Non-CYP Biotransformations 152  
**Phase II Biotransformations (Conjugations)** 156  
 Glucuronidation 156  
 Sulfation 157  
 Acetylation 158  
**Additional Effects on Drug Metabolism** 159  
 Enzyme Induction and Inhibition 159  
 Species 159  
 Sex 160  
 Age 160

## CHAPTER

**12****Methods of Analysis of Drugs and Drug Metabolites**

SANFORD P. MARKEY

- Introduction** 163  
**Choice of Analytical Methodology** 163  
**Chromatographic Separations** 164  
**Absorption and Emission Spectroscopy** 165  
**Immunoaffinity Assays** 166  
**Mass Spectrometry** 167  
**Examples of Current Assay Methods** 170  
 HPLC/UV and HPLC/MS Assay of New Chemical Entities — Nucleoside Drugs 170  
 HPLC/MS/MS Quantitative Assays of Cytochrome P450 Enzyme Activity 173  
 HPLC/UV and Immunoassays of Cyclosporine: Assays for Therapeutic Drug Monitoring 174

Summary of F-ddA, CYP2B6, and Cyclosporine Analyses 177

## CHAPTER

**13****Clinical Pharmacogenetics**

DAVID A. FLOCKHART AND LEIF BERTILSSON

- Introduction 179  
 Hierarchy of Pharmacogenetic Information 180  
 Identification and Selection of Outliers in a Population 181  
 Examples of Important Genetic Polymorphisms 183  
 Drug Absorption 183  
 Drug Distribution 183  
 Drug Elimination 183  
 Mutations That Influence Drug Receptors 190  
 Combined Variants in Drug Metabolism and Receptor Genes: Value of Drug Pathway Analysis 191  
 Conclusions and Future Directions 191

## CHAPTER

**14****Equilibrative and Concentrative Transport Mechanisms**

PETER C. PREUSCH

- Introduction 197  
 Mechanisms of Transport Across Biological Membranes 197  
 Thermodynamics of Membrane Transport 198  
 Passive Diffusion 199  
 Carrier-Mediated Transport: Facilitated Diffusion and Active Transport 201  
 Uptake Mechanisms Dependent on Membrane Trafficking 202  
 Paracellular Transport and Permeation Enhancers 204  
 Description of Selected Membrane Protein Transporters 204  
 ATP-Binding Cassette Superfamily 205  
 Multifacilitator Superfamily Transporters 207  
 Role of Transporters in Pharmacokinetics and Drug Action 209  
 Role of Transporters in Drug Absorption 211  
 Role of Transporters in Drug Distribution 211

- Role of Transporters in Drug Elimination 213  
 Role of Transporters in Drug Interactions 213  
 P-gp Inhibition as an Adjunct to Treating Chemotherapy-Resistant Cancers 214  
 Role of Transporters in Microbial Drug Resistance 215  
 Pharmacogenetics and Pharmacogenomics of Transporters 215  
 Pharmacogenomics of Drug Transport 215  
 Pharmacogenetics of Drug Transport 217  
 Future Directions 220  
 Structural Biology of Membrane Transport Proteins 220  
*In Silico* Prediction of Drug Absorption, Distribution, Metabolism, and Elimination 220

## CHAPTER

**15****Drug Interactions**

SARAH ROBERTSON AND SCOTT PENZAK

- Introduction 229  
 Epidemiology 229  
 Classifications 229  
 Mechanisms of Drug Interactions 230  
 Interactions Affecting Drug Absorption 230  
 Interactions Affecting Drug Distribution 231  
 Interactions Affecting Drug Metabolism 232  
 Interactions Involving Drug Transport Proteins 237  
 Interactions Affecting Renal Excretion 242  
 Prediction and Clinical Management of Drug Interactions 242  
*In Vitro* Screening Methods 242  
 Genetic Variation 243  
 Clinical Management of Drug Interactions 243

## CHAPTER

**16****Biochemical Mechanisms of Drug Toxicity**

ARTHUR J. ATKINSON, JR. AND SANFORD P. MARKEY

- Introduction 249  
 Drug-Induced Methemoglobinemia 249  
 Role of Covalent Binding in Drug Toxicity 252  
 Drug-Induced Liver Toxicity 253  
 Hepatotoxic Reactions Resulting from Covalent Binding of Reactive Metabolites 253

- Immunologically Mediated Hepatotoxic Reactions 255  
 Mechanisms of Other Drug Toxicities 259  
 Systemic Reactions Resulting from Drug Allergy 259  
 Carcinogenic Reactions to Drugs 263  
 Teratogenic Reactions to Drugs 266

## PART

## III

## ASSESSMENT OF DRUG EFFECTS

## CHAPTER

## 17

## Physiological and Laboratory Markers of Drug Effect

ARTHUR J. ATKINSON, JR. AND PAUL ROLAN

- Biological Markers of Drug Effect 275  
 Identification and Evaluation of Biomarkers 277  
 Uses of Biomarkers and Surrogate Endpoints 279  
 Use of Serum Cholesterol as a Biomarker and Surrogate Endpoint 280  
 Application of Serial Biomarker Measurements 282  
 Future Development of Biomarkers 283

## CHAPTER

## 18

## Dose-Effect and Concentration-Effect Analysis

ELIZABETH S. LOWE AND FRANK M. BALIS

- Background 289  
 Drug-Receptor Interactions 290  
 Receptor Occupation Theory 291  
 Receptor-Mediated Effects 292  
 Graded Dose-Effect Relationship 292  
 Dose-Effect Parameters 293  
 Dose Effect and Site of Drug Action 294  
 Quantal Dose-Effect Relationship 295  
 Therapeutic Indices 296  
 Dose Effect and Defining Optimal Dose 297  
 Pharmacodynamic Models 298  
 Fixed-Effect Model 298  
 Maximum-Effect ( $E_{max}$  and Sigmoid  $E_{max}$ ) Models 298

- Linear and Log-Linear Model 299  
 Conclusion 299

## CHAPTER

## 19

## Time Course of Drug Response

NICHOLAS H. G. HOLFORD AND ARTHUR J. ATKINSON, JR.

- Pharmacokinetics and Delayed Pharmacologic Effects 302  
 The Biophase Compartment 302  
 Incorporation of Pharmacodynamic Models 304  
 Physicokinetics — Time Course of Effects due to Physiological Turnover Processes 307  
 Therapeutic Response, Cumulative Drug Effects, and Schedule Dependence 308

## CHAPTER

## 20

## Disease Progress Models

NICHOLAS H. G. HOLFORD, DIANE R. MOULDE, AND CARL C. PECK

- Clinical Pharmacology and Disease Progress 313  
 Disease Progress Models 313  
 "No Progress" Model 313  
 Linear Progress Model 314  
 Asymptotic Progress Model 316  
 Nonzero Asymptote 317  
 Physiological Turnover Models 318  
 Growth Models 318  
 Conclusion 320

## PART

## IV

## OPTIMIZING AND EVALUATING PATIENT THERAPY

## CHAPTER

## 21

## Pharmacological Differences between Men and Women

MAYLEE CHEN, JOSEPH S. BERTINO, JR., MARY J. BERG, AND ANNE N. NAFZIGER

- Pharmacokinetics 325  
 Absorption 326

|  |            |
|--|------------|
| Distribution   | 326        |
| Renal Excretion  | 327        |
| Sex Differences in Metabolic Pathways                          | 327        |
| Drug Transporters  | 329        |
| Drug Metabolism Interactions of Particular Importance to Women | 329        |
| Chronopharmacology, Menstrual Cycle, and Menopause             | 330        |
| <b>Pharmacodynamics</b>  | <b>331</b> |
| Cardiovascular Effects   | 331        |
| Analgesic Effects  | 332        |
| Sex Differences in Immunology and Immunosuppression            | 332        |
| <b>Summary</b>   | <b>334</b> |

## CHAPTER

**22****Drug Therapy in Pregnant and Nursing Women**

CATHERINE S. STIKA AND MARILYNN C. FREDERIKSEN

|   |            |
|---|------------|
| <b>Pregnancy Physiology and its Effects On Pharmacokinetics</b> | <b>340</b> |
| Gastrointestinal Changes  | 340        |
| Cardiovascular Effects  | 340        |
| Blood Composition Changes                                       | 341        |
| Renal Changes   | 342        |
| Hepatic Drug-Metabolizing Changes                               | 342        |
| Peripartum Changes  | 344        |
| Postpartum Changes  | 344        |
| <b>Pharmacokinetic Studies During Pregnancy</b>                 | <b>344</b> |
| Results of Selected Pharmacokinetic Studies in Pregnant Women   | 344        |
| Guidelines for the Conduct of Drug Studies in Pregnant Women    | 347        |
| <b>Placental Transfer of Drugs</b>                              | <b>348</b> |
| <b>Teratogenesis</b>  | <b>349</b> |
| Principles of Teratology  | 350        |
| Measures to Minimize Teratogenic Risk                           | 351        |
| <b>Drug Therapy in Nursing Mothers</b>                          | <b>352</b> |

## CHAPTER

**23****Drug Therapy in Neonates and Pediatric Patients**

ELIZABETH FOX AND FRANK M. BALIS

|                   |            |
|-------------------|------------|
| <b>Background</b> | <b>359</b> |
|-------------------|------------|

|   |            |
|---|------------|
| Chloramphenicol Therapy in Newborns                       | 359        |
| Zidovudine Therapy in Newborns, Infants, and Children     | 360        |
| Development of Federal Regulations                        | 361        |
| <b>Ontogeny and Pharmacology</b>                          | <b>362</b> |
| Drug Absorption   | 362        |
| Drug Distribution   | 363        |
| Drug Metabolism   | 364        |
| Renal Excretion   | 365        |
| <b>Therapeutic Implications of Growth and Development</b> | <b>366</b> |
| Effect on Pharmacokinetics                                | 367        |
| Effect on Pharmacodynamics                                | 370        |
| Effect of Childhood Diseases                              | 370        |
| <b>Conclusions</b>  | <b>371</b> |

## CHAPTER

**24****Drug Therapy in the Elderly**

DARRELL R. ABERNETHY

|   |            |
|---|------------|
| <b>Introduction</b>   | <b>375</b> |
| <b>Pathophysiology of Aging</b>   | <b>375</b> |
| <b>Age-Related Changes in Pharmacokinetics</b>                          | <b>377</b> |
| Age-Related Changes in Renal Clearance                                  | 377        |
| Age-Related Changes in Hepatic and Extrahepatic Drug Biotransformations | 378        |
| <b>Age-Related Changes in Effector System Function</b>                  | <b>379</b> |
| Central Nervous System  | 379        |
| Autonomic Nervous System  | 380        |
| Cardiovascular Function   | 381        |
| Renal Function  | 382        |
| Hematopoietic System and the Treatment of Cancer                        | 383        |
| <b>Drug Groups for Which Age Confers Increased Risk for Toxicity</b>    | <b>383</b> |
| <b>Conclusions</b>  | <b>385</b> |

## CHAPTER

**25****Clinical Analysis of Adverse Drug Reactions**

KARIM ANTON CALIS, EMIL N. SIDAWY, AND LINDA R. YOUNG

|                     |            |
|---------------------|------------|
| <b>Introduction</b> | <b>389</b> |
| Epidemiology        | 389        |
| Definitions         | 389        |



|                                  |     |
|----------------------------------|-----|
| Classification                   | 390 |
| Clinical Detection               | 391 |
| Risk Factors                     | 393 |
| Detection Methods                | 395 |
| Clinical Evaluation              | 395 |
| Causality Assessment             | 396 |
| Reporting Requirements           | 397 |
| ADR Detection in Clinical Trials | 398 |
| Methodology                      | 398 |
| Limitations                      | 399 |
| Reporting Requirements           | 399 |
| Information Sources              | 399 |

## CHAPTER

**26****Quality Assessment of Drug Therapy**

CHARLES E. DANIELS

|  |     |
|--|-----|
| Introduction                                 | 403 |
| Adverse Drug Events                          | 403 |
| Medication Use Process                       | 404 |
| Improving the Quality of Medication Use      | 405 |
| Organizational Influences On Medication Use  |     |
| Quality                                      | 406 |
| Medication Policy Issues                     | 407 |
| Formulary Management                         | 407 |
| Analysis and Prevention of Medication Errors | 409 |
| Medication Use Evaluation                    | 414 |
| Summary                                      | 417 |

## PART

**V****DRUG DISCOVERY AND DEVELOPMENT**

## CHAPTER

**27****Portfolio and Project Planning and Management in the Drug Discovery, Development, and Review Process**

CHARLES GRUDZINSKAS

|                      |     |
|----------------------|-----|
| Introduction         | 423 |
| What Is a Portfolio? | 423 |

|   |     |
|---|-----|
| What Is Project Planning and Management?          | 424 |
| Portfolio Design, Planning, and Management        | 424 |
| Maximizing Portfolio Value                        | 425 |
| Portfolio Design                                  | 425 |
| Portfolio Planning                                | 426 |
| Portfolio Management                              | 427 |
| Portfolio Optimization Using Sensitivity Analysis | 428 |
| Project Planning and Management                   | 429 |
| Project Planning                                  | 429 |
| The Project Management Triangle                   | 430 |
| The Project Cycle                                 | 431 |
| Project Planning and Management Tools             | 431 |
| Decision Trees                                    | 432 |
| Milestone Charts                                  | 432 |
| PERT/CPM Charts                                   | 432 |
| Gantt Charts                                      | 433 |
| Work Breakdown Structures                         | 433 |
| Financial Tracking                                | 434 |
| Project Scheduling                                | 434 |
| Project Team Management and Decision-Making       | 434 |
| Core Project Teams                                | 434 |
| Project Team Leadership and Project Support       | 435 |
| FDA Project Teams                                 | 435 |
| Effective Project Meetings                        | 436 |
| Resource Allocation                               | 436 |
| Effective Project Decision-Making                 | 436 |
| Process Leadership and Benchmarking               | 436 |

## CHAPTER

**28****Drug Discovery**

SHANNON DECKER AND EDWARD A. SAUSVILLE

|   |     |
|---|-----|
| Introduction                                    | 439 |
| Definition of Drug Targets                      | 439 |
| Empirical Drug Discovery                        | 440 |
| Rational Drug Discovery                         | 440 |
| Generating Diversity                            | 443 |
| Natural Products                                | 443 |
| Chemical Compound Libraries                     | 443 |
| Definition of Lead Structures                   | 444 |
| Biochemical Screens                             | 444 |
| Cell-Based Screens                              | 444 |
| Structure-Based Drug Design                     | 445 |
| Qualifying Leads for Transition to Early Trials | 445 |

## CHAPTER

**29****Preclinical Drug Development**

CHRIS H. TAKIMOTO AND MICHAEL WICK

- INTRODUCTION** 449
- Components of Preclinical Drug Development** 450
- In Vitro* Studies 450
  - Drug Supply and Formulation 451
  - In Vivo* Studies — Efficacy Testing in Animal Models 452
  - In Vivo* Studies — Preclinical Pharmacokinetic and Pharmacodynamic Testing 455
  - In Vivo* Studies — Preclinical Toxicology 455
- Drug Development Programs at the NCI** 456
- History 456
  - The 3-Cell-Line Prescreen and 60-Cell-Line Screen 456
  - NCI Drug Development Process 459
- The Challenge — Molecularly Targeted Therapies and New Paradigms for Clinical Trials** 459

## CHAPTER

**30****Animal Scale-Up**

ROBERT L. DEDRICK AND ARTHUR J. ATKINSON, JR.

- Introduction** 463
- Allometry** 463
- Use of Allometry to Predict Human Pharmacokinetic Parameters 465
  - Use of Allometry in Designing Intraperitoneal Dose Regimens 465
- Physiological Pharmacokinetics** 467
- In Vitro-in Vivo* Correlation of Hepatic Metabolism** 469

## CHAPTER

**31****Phase I Clinical Studies**

JERRY M. COLLINS

- Introduction** 473
- Disease-Specific Considerations** 473
- Starting Dose and Dose Escalation** 474
- Modified Fibonacci Escalation Scheme 474
  - Pharmacologically Guided Dose Escalation 475

- Interspecies Differences in Drug Metabolism 475
- Active Metabolites 476
- Beyond Toxicity 477

## CHAPTER

**32****Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules**

PAMELA D. GARZONE

- Introduction** 479
- Monoclonal Antibodies 479
  - Assay of Macromolecules 482
  - Interspecies Scaling of Macromolecules: Predictions in Humans 482
- Pharmacokinetic Characteristics of Macromolecules** 483
- Endogenous Concentrations 483
  - Absorption 485
  - Distribution 487
  - Metabolism 489
  - Renal Excretion 490
  - Application of Sparse Sampling and Population Kinetic Methods 492
- Pharmacodynamics** 494
- Models 494
  - Regimen Dependency 496

## CHAPTER

**33****Design of Clinical Development Programs**

CHARLES GRUDZINSKAS

- Introduction** 501
- Phases, Size, and Scope of Clinical Development Programs** 501
- Global Development 501
  - Clinical Drug Development Phases 502
  - Drug Development Time and Cost — A Changing Picture 502
  - Impact of Regulation on Clinical Development Programs 504
- Goal and Objectives of Clinical Drug Development** 505
- Objective 1 — Clinical Pharmacology and Pharmacometrics 506
  - Objective 2 — Safety 506

|   |            |
|---|------------|
| Objective 3 — Activity  | 506        |
| Objective 4 — Effectiveness   | 506        |
| Objective 5 — Differentiation   | 506        |
| Objective 6 — Preparation of a Successful<br>NDA/BLA Submission               | 506        |
| Objective 7 — Market Expansion and<br>Postmarketing Surveillance              | 506        |
| <b>Critical Drug Development Paradigms</b>                                    | <b>507</b> |
| Label-Driven Question-Based Clinical<br>Development Plan Paradigm             | 507        |
| Differentiation Paradigm  | 507        |
| Drug Action → Response → Outcome → Benefit<br>Paradigm                        | 508        |
| Learning vs Confirming Paradigm   | 508        |
| Decision-Making Paradigm  | 508        |
| Fail Early/Fail Cheaply Paradigm  | 508        |
| <b>Critical Clinical Drug Development Decision<br/>Points</b>                 | <b>509</b> |
| Which Disease State?  | 510        |
| What Are the Differentiation Targets?   | 511        |
| Is the Drug "Reasonably Safe" for FIH<br>Trials?                              | 512        |
| Starting Dose for the FIH Trial   | 512        |
| Have Clinical Proof of Mechanism and Proof<br>of Concept Been Obtained?       | 512        |
| Have the Dose, Dose Regimen, and Patient<br>Population Been Characterized?    | 513        |
| Will the Product Grow in the Postmarketing<br>Environment?                    | 513        |
| Will the Clinical Development Program Be<br>Adequate for Regulatory Approval? | 513        |

|   |            |
|---|------------|
| <b>Learning Contemporary Clinical Drug<br/>Development</b>        | <b>514</b> |
| Courses and Other Educational<br>Opportunities                    | 514        |
| Failed Clinical Drug Development Programs as<br>Teaching Examples | 515        |

## CHAPTER

**34****Role of the FDA in Guiding  
Drug Development**LAWRENCE J. LESKO AND CHANDRA G.  
SAHAJWALLA

|  |            |
|--|------------|
| Why does the FDA Get Involved in Drug<br>Development?  | 520        |
| When does the FDA Get Involved in Drug<br>Development? | 520        |
| How does the FDA Guide Drug Development?               | 521        |
| What Are FDA Guidances?                                | 523        |
| <b>Appendix I</b>                                      |            |
| Abbreviated Tables of Laplace Transforms               | 527        |
| <b>Appendix II</b>                                     |            |
| ARTHUR J. ATKINSON, JR.                                |            |
| Answers to Study Problems                              | 529        |
| <b>Index</b>   | <b>537</b> |